Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture
(NASDAQ: SGMO) $6.47 + 0.16 (2.536%) High
6.53
Low
6.32
Volume 803,244 4:00 PM ET on May 24, 2016 Delayed at least 20 minutes

Investor Presentation

Corporate Fact Sheet